ATE186745T1 - Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern - Google Patents

Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern

Info

Publication number
ATE186745T1
ATE186745T1 AT96900937T AT96900937T ATE186745T1 AT E186745 T1 ATE186745 T1 AT E186745T1 AT 96900937 T AT96900937 T AT 96900937T AT 96900937 T AT96900937 T AT 96900937T AT E186745 T1 ATE186745 T1 AT E186745T1
Authority
AT
Austria
Prior art keywords
antibodies
pct
antigen
release
bond
Prior art date
Application number
AT96900937T
Other languages
English (en)
Inventor
Hilmar Lemke
Hinrich-Peter Hansen
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8218912&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE186745(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of ATE186745T1 publication Critical patent/ATE186745T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
AT96900937T 1995-01-18 1996-01-11 Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern ATE186745T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95100591 1995-01-18

Publications (1)

Publication Number Publication Date
ATE186745T1 true ATE186745T1 (de) 1999-12-15

Family

ID=8218912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96900937T ATE186745T1 (de) 1995-01-18 1996-01-11 Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern

Country Status (9)

Country Link
US (1) US6033876A (de)
EP (1) EP0805871B2 (de)
JP (1) JP3066983B2 (de)
AT (1) ATE186745T1 (de)
AU (1) AU4485696A (de)
CA (1) CA2210620C (de)
DE (1) DE69605181T3 (de)
ES (1) ES2141467T5 (de)
WO (1) WO1996022384A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7090843B1 (en) † 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
BR0306808A (pt) * 2002-01-09 2005-08-30 Medarex Inc Anticorpos monoclonais humanos contra cd30
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US7470775B2 (en) * 2002-06-07 2008-12-30 The United States Of America As Represented By The Department Of Health And Human Services Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins
EP1378523A1 (de) * 2002-07-01 2004-01-07 STEIN, Harald, Prof. Dr. Anti-cd30-antikörper und deren verwendungen
EP1545613B9 (de) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
ZA200703154B (en) 2004-10-01 2008-09-25 Medarex Inc Methods of treating CD30 positive lymphomas
US8207303B2 (en) * 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
WO2006116246A2 (en) * 2005-04-25 2006-11-02 Medarex, Inc. Method of treating cd30 positive lymphomas
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
US20090175886A1 (en) * 2006-01-17 2009-07-09 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
WO2008025020A2 (en) * 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
TW200918089A (en) 2007-07-16 2009-05-01 Genentech Inc Humanized anti-CD79b antibodies and immunoconjugates and methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
ES2848323T3 (es) 2008-01-31 2021-08-06 Inst Nat Sante Rech Med Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
SI2657253T1 (sl) 2008-01-31 2017-10-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
EP3593812A3 (de) 2014-03-15 2020-05-27 Novartis AG Behandlung von krebs mithilfe eines chimären antigenrezeptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
PL3262071T3 (pl) 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Sposób stosowania immunokoniugatów anty-CD79b
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN107849096B (zh) 2015-05-30 2022-05-24 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3331913A1 (de) 2015-08-07 2018-06-13 Novartis AG Behandlung von krebs mithilfe von chimären cd3-rezeptor-proteinen
JP7118887B2 (ja) 2015-11-23 2022-08-16 ノバルティス アーゲー 最適化されたレンチウイルス移入ベクターおよびその使用
WO2017114497A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
NZ752394A (en) 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
EP3577134A1 (de) 2017-01-31 2019-12-11 Novartis AG Behandlung von krebs mit chimären t-zellrezeptorproteinen mit mehreren spezifitäten
EP3589647A1 (de) 2017-02-28 2020-01-08 Novartis AG Shp-inhibitor-zusammensetzungen und verwendungen zur chimären antigenrezeptortherapie
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019027935A1 (en) 2017-07-31 2019-02-07 Tizona Therapeutics ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
AU2018355427A1 (en) 2017-10-25 2020-04-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (de) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Zusammensetzungen und verfahren zur immunonkologie
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2021055329A1 (en) 2019-09-16 2021-03-25 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4165169A1 (de) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitoren und deren verwendungen
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
AU2022213913A1 (en) 2021-01-27 2023-08-17 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202309294A (zh) 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
AU6909191A (en) * 1989-11-20 1991-06-13 Parker, David L. Improved cd-30 antibodies and fragments thereof
DE4205938A1 (de) * 1992-02-27 1993-09-02 Medac Klinische Spezialpraep Immunotoxine

Also Published As

Publication number Publication date
EP0805871B2 (de) 2006-02-22
CA2210620C (en) 2004-06-22
EP0805871B1 (de) 1999-11-17
DE69605181T2 (de) 2000-04-06
ES2141467T5 (es) 2006-07-16
CA2210620A1 (en) 1996-07-25
WO1996022384A1 (en) 1996-07-25
JP3066983B2 (ja) 2000-07-17
JPH10502544A (ja) 1998-03-10
DE69605181T3 (de) 2006-08-24
EP0805871A1 (de) 1997-11-12
ES2141467T3 (es) 2000-03-16
DE69605181D1 (de) 1999-12-23
US6033876A (en) 2000-03-07
AU4485696A (en) 1996-08-07

Similar Documents

Publication Publication Date Title
ATE186745T1 (de) Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
NO965239D0 (no) Monoklonalt antistoff mot CD44v6
MX2007000998A (es) Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
MX9603773A (es) Anticuerpos monoclonales anti-interleucina-8 para el tratamiento de trastornos inflamatorios.
ATE302411T1 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
WO2003078468A3 (de) Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
Getahun et al. Studies on the mechanism by which antigen‐specific IgG suppresses primary antibody responses: evidence for epitope masking and decreased localization of antigen in the spleen
DE60034564D1 (de) Menschlicher cytokinrezeptor
ATE328611T1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene,daraus entwickelte impfstoffe sowie deren verwendung
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
DE69322783T2 (de) Monoklonale Antikörper gegen Glykoprotein P
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
ES2119992T3 (es) Anticuerpos especificos de 6-o-metilguanina-adn-metiltransferasa (mgmt).
NZ515382A (en) OX2 receptor homologs
DE69524242T2 (de) Breit-reaktive opsonische antikörper, die mit gemeinsamen staphylococcus-antigenen reagieren
UA93478C2 (ru) Выделенное моноклональное антитело человека, kotopoe связывается c cd20, и его применение
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
NZ335545A (en) Monoclonal dendritic cell (DC)-specific antibodies that binds to DC activated antigen CMRF-56

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties